(Adnkronos) - Contro virus respiratorio sinciziale (Rsv) è disponibile ora un vaccino specifico per adulti a rischio e anziani. Sull’impatto di tale novità nella prevenzione di una patologia respiratoria che causa la bronchiolite nei bambini e infezioni respiratorie gravi, si sono confrontati a Roma esperti nel corso di un incontro con la stampa.
Category
🗞
NewsTranscript
00:0089% of respiratory disease deaths have been recorded over 65 years for a total of 5,800 people, against a total of 116 up to 4 years of age.
00:18These are the data from an American study on the mortality rate for RSV between 1999 and 2018, which underlines that such a virus represents a significant threat to public health, where adults are perhaps the most at risk.
00:32It was discussed during the press conference of GSK held in Rome, where it was discussed the threat, the epidemiology, the impact and the solutions that concern this type of virus.
00:43RSV is a virus that is transmitted by air from person to person and produces effects on the high and low respiratory tracts, from simple colds to pneumonia, deep bronchitis.
01:00It is obviously a respiratory commitment, a respiratory insufficiency that, depending on people, in older people who may have chronic diseases, other intercourse diseases, such as morbidity, really becomes a serious virus.
01:14RSV can also be said to be a really serious virus.
01:20The approval of the adjuvated vaccine against the syncytial respiratory virus of GSK represents a fundamental turn to protect the vulnerable population for age or other pathologies, offering a new tool to defend against this infection.
01:35The characteristics of this vaccine are mainly the fact that it has been developed specifically for the target population and therefore for the adult population with a high level of immunosuppression.
01:49As a result, both an antigen and a specific antigen, i.e. the protein F, have been combined in its conformation and profusion to what is called an adjuvant system.
02:00The adjuvant system, in particular the AS01E system, has been designed specifically to increase the immune response and therefore provide greater protection to this particularly vulnerable population.
02:15According to the scientific evidence of the HTA study, the vaccine against the syncytial respiratory virus represents an effective technology for at least three consecutive seasons.
02:25Of this, I would like to clarify, it is the only technology we have given, so let's say complete. It is an effective and safe vaccine that protects the individual, protects the community and is based on the protection of all and on the evidence that we have available and that we hope that our decision-makers can make the right decisions in the area of protecting the community.
02:45And therefore of anti-RSV vaccination, let's remember it, a problem not only pediatric, but a problem of adults at risk and of the elderly.